These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 15553667)

  • 21. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
    Matsushita N; Aruga A; Inoue Y; Kotera Y; Takeda K; Yamamoto M
    Oncol Rep; 2013 Mar; 29(3):951-9. PubMed ID: 23314271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes.
    Hofmann UB; Voigt H; Andersen MH; Straten PT; Becker JC; Eggert AO
    Eur J Immunol; 2009 May; 39(5):1419-24. PubMed ID: 19337999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
    Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
    J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PolyI:C and mouse survivin artificially embedding human 2B peptide induce a CD4+ T cell response to autologous survivin in HLA-A*2402 transgenic mice.
    Kasamatsu J; Takahashi S; Azuma M; Matsumoto M; Morii-Sakai A; Imamura M; Teshima T; Takahashi A; Hirohashi Y; Torigoe T; Sato N; Seya T
    Immunobiology; 2015 Jan; 220(1):74-82. PubMed ID: 25257859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
    Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
    Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma.
    Inoda S; Morita R; Hirohashi Y; Torigoe T; Asanuma H; Nakazawa E; Nakatsugawa M; Tamura Y; Kamiguchi K; Tsuruma T; Terui T; Ishitani K; Hashino S; Wang Q; Greene MI; Hasegawa T; Hirata K; Asaka M; Sato N
    Exp Mol Pathol; 2011 Feb; 90(1):55-60. PubMed ID: 20950610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer.
    Kibe S; Yutani S; Motoyama S; Nomura T; Tanaka N; Kawahara A; Yamaguchi T; Matsueda S; Komatsu N; Miura M; Hinai Y; Hattori S; Yamada A; Kage M; Itoh K; Akagi Y; Sasada T
    Cancer Immunol Res; 2014 Dec; 2(12):1154-62. PubMed ID: 25351849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine.
    Shima H; Kutomi G; Satomi F; Imamura M; Kimura Y; Mizuguchi T; Watanabe K; Takahashi A; Murai A; Tsukahara T; Kanaseki T; Hirohashi Y; Iwayama Y; Tsuruma T; Kameshima H; Sato N; Torigoe T; Takemasa I
    Cancer Immunol Immunother; 2018 Oct; 67(10):1603-1609. PubMed ID: 30069687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.
    Fuessel S; Meye A; Schmitz M; Zastrow S; Linné C; Richter K; Löbel B; Hakenberg OW; Hoelig K; Rieber EP; Wirth MP
    Prostate; 2006 Jun; 66(8):811-21. PubMed ID: 16482569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine.
    Takeuchi H; Morton DL; Elashoff D; Hoon DS
    Int J Cancer; 2005 Dec; 117(6):1032-8. PubMed ID: 15986442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antitumor immunotherapy with the use of synthetic fragments of survivin].
    Volkova TD; Koroev DO; Titova MA; Oboznaia MB; Filatova MP; Pankratov AA; Morozova NB; Zolotavkina IuB; Iakubovskaia RI; Vol'pina OM
    Bioorg Khim; 2008; 34(4):457-63. PubMed ID: 18695717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas.
    Suga K; Yamamoto T; Yamada Y; Miyatake S; Nakagawa T; Tanigawa N
    Oncol Rep; 2005 May; 13(5):891-7. PubMed ID: 15809755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antibodies to synthetic peptides for the detection of survivin in tumor tissues].
    Akhidova EV; Volkova TD; Koroev DO; Kim IaS; Filatova MP; Vladimirova NM; Karmakova TA; Zavalishina LE; Andreeva IuIu; Vol'pina OM
    Bioorg Khim; 2010; 36(2):178-86. PubMed ID: 20531475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS.
    Yoshitake Y; Fukuma D; Yuno A; Hirayama M; Nakayama H; Tanaka T; Nagata M; Takamune Y; Kawahara K; Nakagawa Y; Yoshida R; Hirosue A; Ogi H; Hiraki A; Jono H; Hamada A; Yoshida K; Nishimura Y; Nakamura Y; Shinohara M
    Clin Cancer Res; 2015 Jan; 21(2):312-21. PubMed ID: 25391695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors.
    Murahashi M; Hijikata Y; Yamada K; Tanaka Y; Kishimoto J; Inoue H; Marumoto T; Takahashi A; Okazaki T; Takeda K; Hirakawa M; Fujii H; Okano S; Morita M; Baba E; Mizumoto K; Maehara Y; Tanaka M; Akashi K; Nakanishi Y; Yoshida K; Tsunoda T; Tamura K; Nakamura Y; Tani K
    Clin Immunol; 2016 May; 166-167():48-58. PubMed ID: 27072896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.
    Mazzaferro V; Coppa J; Carrabba MG; Rivoltini L; Schiavo M; Regalia E; Mariani L; Camerini T; Marchianò A; Andreola S; Camerini R; Corsi M; Lewis JJ; Srivastava PK; Parmiani G
    Clin Cancer Res; 2003 Aug; 9(9):3235-45. PubMed ID: 12960108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survivin minigene DNA vaccination is effective against neuroblastoma.
    Fest S; Huebener N; Bleeke M; Durmus T; Stermann A; Woehler A; Baykan B; Zenclussen AC; Michalsky E; Jaeger IS; Preissner R; Hohn O; Weixler S; Gaedicke G; Lode HN
    Int J Cancer; 2009 Jul; 125(1):104-14. PubMed ID: 19291796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Full-length dominant-negative survivin for cancer immunotherapy.
    Pisarev V; Yu B; Salup R; Sherman S; Altieri DC; Gabrilovich DI
    Clin Cancer Res; 2003 Dec; 9(17):6523-33. PubMed ID: 14695157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.